Keywords
bolalar
klinik belgilar
immunologik mexanizmlar
mikrobiologik muhit
diagnostika
terapiya
individualizatsiya
optimallashtirish
strategiyalar
How to Cite
Abstract
Maqola bolalarda bronxial astmaning klinik, immunologik va mikrobiologik aspektlarini o‘rganish hamda davolash taktikasini optimallashtirishga bag‘ishlangan. Klinika, immunologiya va mikrobiologiya sohalaridagi tekshiruvlar asosida bronxial astmaning patogenezi, rivojlanish omillari va davolash usullari tahlil qilingan. Maqolaning asosiy maqsadi — bolalarda bronxial astmani samarali davolash uchun klinik, immunologik va mikrobiologik tekshiruvlarga asoslangan davolash taktikasini ishlab chiqish. Kasallikning erta diagnostikasi va individual davolash yondashuvlarini ishlab chiqish orqali astmani nazorat qilish va bolalar hayotini yaxshilashga erishish. Tadqiqot natijalariga ko‘ra, astma bolalarda nafas yo‘llarining surunkali yallig‘lanishi va immunologik buzilishlar bilan bog‘liq. IgE antitanalari va T-hujayra reaksiyalarining kuchayishi astma rivojlanishining asosiy omillari sifatida qayd etildi. Mikrobiologik infeksiyalar kasallik xurujlarini kuchaytirishi aniqlangan. Individual yondashuvlar, immunoterapiya va infeksiyaga qarshi davolash astma xurujlarini kamaytirishga yordam berdi. Ushbu maqola bolalar bronxial astmasining klinik, immunologik va mikrobiologik aspektlarini integratsiyalab, davolash taktikasini yangicha yondashuvlar bilan takomillashtirishni taklif etadi.
References
1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2023 update.
2. Agache, I., & Akdis, C. A. (2021). Precision medicine and asthma biomarkers: challenges and opportunities. Allergy, 76(4), 1222-1235.
3. Jackson, D. J., & Hartert, T. V. (2018). Asthma phenotypes and endotypes: an evolving paradigm for classification. The Lancet, 392(10156), 2049-2062.
4. Reddel, H. K., Bateman, E. D., & Bousquet, J. (2018). Global Initiative for Asthma (GINA) strategy: A roadmap for asthma control. European Respiratory Journal, 51(5), 1702171.
5. Fajt, M. L., & Wenzel, S. E. (2020). Asthma phenotypes and the use of biologic medications in asthma treatment. Journal of Allergy and Clinical Immunology: In Practice, 8(2), 461-466.
6. Mukherjee, M., & Nair, P. (2017). Autoimmune responses in severe asthma. Journal of Leukocyte Biology, 101(3), 635-641.
7. Busse, W. W., & Lemanske, R. F. (2018). Advances in immunology: Asthma. Journal of Allergy and Clinical Immunology, 142(6), 1411-1421.
8. Peters, M. C., & Fahy, J. V. (2017). Metabolic consequences of obesity as an "asthma endotype". The Journal of Allergy and Clinical Immunology: In Practice, 5(6), 1574-1577.
9. Fahy, J. V. (2020). Type 2 inflammation in asthma—present in most, absent in many. Nature Reviews Immunology, 20(1), 57-68.
10. Martinez, F. D., & Vercelli, D. (2019). Asthma. The Lancet, 392(10153), 1360-1372.
11. Pavord, I. D., & Bush, A. (2018). Asthma: Time to redefine airways diseases?. The Lancet, 391(10118), 297-299.
12. Fitzpatrick, A. M., & Moore, W. C. (2019). Severe asthma phenotypes: How should they guide evaluation and treatment?. The Journal of Allergy and Clinical Immunology: In Practice, 7(3), 901-909.
13. Schatz, M., Rosenwasser, L. J., & Busse, W. W. (2020). Asthma across the ages: Adult asthma. Journal of Allergy and Clinical Immunology, 145(6), 1584-1586.
14. Castro, M., & Kraft, M. (2018). Update in asthma 2017. American Journal of Respiratory and Critical Care Medicine, 197(3), 283-296.
15. Wenzel, S. E. (2021). Treatment of severe asthma in adolescents and adults. The New England Journal of Medicine, 384(13), 1287-1300.
16. Menzies-Gow, A., Corren, J., & Bel, E. H. (2021). Biological therapies in severe asthma: A European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 58(1), 2100058.
17. Pavord, I. D., & Chanez, P. (2019). Emerging biologics in asthma: Impact on phenotype, endotype, and outcomes. The Lancet Respiratory Medicine, 7(2), 120-128.
18. Brusselle, G., & Bracke, K. (2019). Targeting immune pathways for the treatment of severe asthma: Is there a future beyond type 2 inflammation?. The Journal of Allergy and Clinical Immunology: In Practice, 7(6), 1810-1817.
19. Kuruvilla, M. E., Lee, F. E., & Lee, G. B. (2019). Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clinical Reviews in Allergy & Immunology, 56(2), 219-233.
20. Masoli, M., Fabian, D., Holt, S., & Beasley, R. (2018). The global burden of asthma: Executive summary of the GINA dissemination committee report. European Respiratory Journal, 17(5), 143-151.
21. Holguin, F., Cardet, J. C., Chung, K. F., & Khatri, S. (2019). Management of severe asthma: A European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 54(2), 1900983.
22. Castro-Rodriguez, J. A., & Holberg, C. J. (2020). Association of obesity with asthma symptoms, exacerbations, and health care utilization. Annals of the American Thoracic Society, 17(3), 322-329.
23. Hinks, T. S. C., & Moffatt, M. F. (2020). Identifying type 2 inflammation in asthma. The Journal of Allergy and Clinical Immunology, 145(6), 1481-1493.
This work is licensed under a Creative Commons Attribution 4.0 International License.